{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:06:36Z","timestamp":1788948396758,"version":"build-2803163510"},"reference-count":19,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Scleroderma Raynaud\u2019s United Kingdom","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Scleroderma Relat Disord"],"accepted":{"date-parts":[[2026,1,11]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Associations between Raynaud\u2019s phenomenon (RP) and body mass index (BMI), fibromyalgia syndrome (FMS) and migraine have been reported but their influence on the lived experience of RP is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional electronic survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A social media-based awareness campaign organised by Scleroderma &amp; Raynaud\u2019s UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>4141 respondents with RP, including 3279 with primary RP (PRP), 476 with systemic sclerosis-related RP (SSc-RP) and 386 with other systemic autoimmune rheumatic disease-related RP (SARD-RP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>RP symptom characteristics (colour change patterns, pain, numbness, tingling and thumb involvement) and their associations with BMI, FMS and migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In PRP, low BMI correlated with higher prevalence of cyanosis (55.1% vs 41.2%), hyperaemia (48.2% vs 41.3%), triphasic change (30.4% vs 23.0%) and thumb involvement (36.0% vs 27.0%) compared with high BMI. In PRP, concomitant FMS was associated with higher prevalence of pain (77.7% vs 57.4%), cyanosis (53.8% vs 45.4%), tingling (72.6% vs 62.8%) and thumb involvement (46.2% vs 27.2%) compared with those without FMS. Higher prevalence of pain was reported by FMS respondents with SSc-RP (82.8% vs 69.9%)\u2009and SARD-RP (84.1% and 70.9%,\u2009respectively). In PRP, migraine was associated with higher prevalence of cyanosis (50.0% vs 44.9%), hyperaemia (50.3% vs 43.7%), pain (69.0% vs 56.2%) and thumb involvement (33.4% vs 27.1%). Migraine was associated with higher prevalence of hyperaemia and pain in SARD-RP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BMI, FMS and migraine influence the lived experience of RP, particularly in PRP. FMS is associated with a greater pain burden, whereas low BMI and migraine are associated with prominent vasospastic features. These aetiopathogenic drivers influence RP symptomatology, with implications for management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jsrd-2026-000008","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:50:20Z","timestamp":1779803420000},"page":"e000008","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of comorbidities and patient demographics on Raynaud\u2019s symptom characteristics: implications for diagnosis and management"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8494-3475","authenticated-orcid":false,"given":"Reshma","family":"Seomore","sequence":"first","affiliation":[{"name":"Department of Rheumatology, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-3358","authenticated-orcid":false,"given":"Matthew","family":"Wells","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Bristol NHS Trust, Bristol, UK"},{"name":"Department of Clinical Specialties & Related Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ula","family":"Tymoszuk","sequence":"additional","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithi","family":"Ahmed-Richards","sequence":"additional","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Farrington","sequence":"additional","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-7926","authenticated-orcid":false,"given":"Ariane L.","family":"Herrick","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK and National Institute for Health and Care Research (NIHR), Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK and National Institute for Health and Care Research (NIHR), Manchester, UK"},{"name":"Northern Care Alliance NHS Foundation Trust, Salford Care Organisation, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Jeffries-Owen","sequence":"additional","affiliation":[{"name":"Scleroderma and Raynaud\u2019s UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Pauling","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Bristol NHS Trust, Bristol, UK"},{"name":"Musculoskeletal Research Unit, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026090902101608000_11.1.e000008.1","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","article-title":"Raynaud\u2019s phenomenon-an update on diagnosis, classification and management","volume":"38","author":"Pauling","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2026090902101608000_11.1.e000008.2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/rheumatology\/key026","article-title":"The patient experience of Raynaud\u2019s phenomenon in systemic sclerosis","volume":"58","author":"Pauling","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026090902101608000_11.1.e000008.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006389","article-title":"Prevalence, risk factors and associations of primary Raynaud\u2019s phenomenon: systematic review and meta-analysis of observational studies","volume":"5","author":"Garner","year":"2015","journal-title":"BMJ Open"},{"key":"2026090902101608000_11.1.e000008.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev002"},{"key":"2026090902101608000_11.1.e000008.5","doi-asserted-by":"crossref","first-page":"152521","DOI":"10.1016\/j.semarthrit.2024.152521","article-title":"Clinically relevant differences between primary Raynaud\u2019s phenomenon and secondary to connective tissue disease","volume":"68","author":"Di Donato","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026090902101608000_11.1.e000008.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1932.02740700012003"},{"key":"2026090902101608000_11.1.e000008.7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/03009742.2020.1780310","article-title":"Low body weight and involuntary weight loss are associated with Raynaud\u2019s phenomenon in both men and women","volume":"50","author":"Abdulle","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2026090902101608000_11.1.e000008.8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00296-016-3483-6","article-title":"Symptoms of Raynaud\u2019s phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology","volume":"36","author":"Scolnik","year":"2016","journal-title":"Rheumatol Int"},{"key":"2026090902101608000_11.1.e000008.9","doi-asserted-by":"crossref","first-page":"23971983251369577","DOI":"10.1177\/23971983251369577","article-title":"Pain and fatigue in systemic sclerosis: Practical strategies for non-pharmacological management","volume":"10","author":"Bonomi","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"2026090902101608000_11.1.e000008.10","first-page":"35","article-title":"Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria","volume":"35 Suppl 105","author":"Perrot","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2026090902101608000_11.1.e000008.11","first-page":"1187","article-title":"Association between Raynaud\u2019s phenomenon and migraine in a random population of hospital employees","volume":"20","author":"O\u2019Keeffe","year":"1993","journal-title":"J Rheumatol"},{"key":"2026090902101608000_11.1.e000008.12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350160096017"},{"key":"2026090902101608000_11.1.e000008.13","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.amjcard.2013.01.269","article-title":"Prevalence of migraine and Raynaud phenomenon in women with apical ballooning syndrome (Takotsubo or stress cardiomyopathy)","volume":"111","author":"Scantlebury","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026090902101608000_11.1.e000008.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010364","article-title":"Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies","volume":"6","author":"Fayaz","year":"2016","journal-title":"BMJ Open"},{"key":"2026090902101608000_11.1.e000008.15","doi-asserted-by":"crossref","first-page":"112234","DOI":"10.1016\/j.biopha.2021.112234","article-title":"Association between migraine prevalence, treatment with proton-pump inhibitors and CYP2C19 phenotypes in UK Biobank","volume":"143","author":"Pisanu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2026090902101608000_11.1.e000008.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00781.x"},{"key":"2026090902101608000_11.1.e000008.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-87421-w","article-title":"Disproportionality analysis of Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system","volume":"15","author":"Lee","year":"2025","journal-title":"Sci Rep"},{"key":"2026090902101608000_11.1.e000008.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7004.541"},{"key":"2026090902101608000_11.1.e000008.19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3598"}],"container-title":["Journal of Scleroderma and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jsrd-2026-000008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:10:26Z","timestamp":1788945026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jsrd.bmj.com\/lookup\/doi\/10.1136\/jsrd-2026-000008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,26]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jsrd-2026-000008"],"URL":"https:\/\/doi.org\/10.1136\/jsrd-2026-000008","relation":{},"ISSN":["2397-1983","2397-1991"],"issn-type":[{"value":"2397-1983","type":"print"},{"value":"2397-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}